|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013018,
umls-concept:C0039194,
umls-concept:C0085358,
umls-concept:C0205263,
umls-concept:C0439851,
umls-concept:C0441655,
umls-concept:C0574032,
umls-concept:C1332714,
umls-concept:C1332717,
umls-concept:C1395724,
umls-concept:C1413244,
umls-concept:C1552596,
umls-concept:C1706438,
umls-concept:C1709854,
umls-concept:C1947931,
umls-concept:C2323499,
umls-concept:C2698600
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-7-12
|
|
pubmed:abstractText |
Donor lymphocyte infusions (DLIs) provide effectivetherapy for patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Previous studies have suggested that depletion of CD8+ T cells from the infused donor lymphocytes can reduce the incidence of graft-versus-host disease associated with DLI without reducing antileukemia activity. In this situation however, the immune effector cells responsible for tumor rejection have not been identified. The goal of this study was to characterize these effector populations.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2052-60
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12114403-Adult,
pubmed-meshheading:12114403-Antigens, CD3,
pubmed-meshheading:12114403-Antigens, CD8,
pubmed-meshheading:12114403-Bone Marrow Cells,
pubmed-meshheading:12114403-Bone Marrow Transplantation,
pubmed-meshheading:12114403-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12114403-CD8-Positive T-Lymphocytes,
pubmed-meshheading:12114403-Clone Cells,
pubmed-meshheading:12114403-Cytotoxicity, Immunologic,
pubmed-meshheading:12114403-Female,
pubmed-meshheading:12114403-Graft vs Host Disease,
pubmed-meshheading:12114403-Hematopoiesis,
pubmed-meshheading:12114403-Humans,
pubmed-meshheading:12114403-Interferon-gamma,
pubmed-meshheading:12114403-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12114403-Lymphocyte Depletion,
pubmed-meshheading:12114403-Lymphocyte Transfusion,
pubmed-meshheading:12114403-Male,
pubmed-meshheading:12114403-Middle Aged,
pubmed-meshheading:12114403-Receptors, Antigen, T-Cell,
pubmed-meshheading:12114403-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
|
|
pubmed:affiliation |
Center for Hematologic Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
